Providing market intelligence for more than 35 years

In The News

Cord nevers don't know what they're missing, and pay TV needs to show them, says Parks' Sappington

Brett Sappington, senior director of research at Parks Associates, kicked off the first annual Pay TV Show detailing some of the emerging challenges and opportunities for the pay TV space.

He broke out the virtual MVPD space by operators (DirecTV Now, Sling TV), content producers (Hulu and Philo), online brands (YouTubeTV), consumer electronics makers (Playstation Vue) and OTT services (FuboTV). But he also pointed to the growing number of premium channels, sports networks, cable channels and broadcasters that are increasingly going over the top. He said that cable channels and content companies are getting more involved because they realize they need have a bigger market.

From the article "Cord nevers don't know what they're missing, and pay TV needs to show them, says Parks' Sappington" by Ben Munson.

Previously In The News

Parks: US Churn Rate For OTT Services Is 19%

This is according to Parks Associates’ latest ‘OTT Video Market Tracker’ stats, which said that overall churn rate for OTT services has been roughly stable for the past year. At the end of 2015, 20...

One in five US subscribers now ‘dissatisfied’ with pay TV service

Some 20% of US pay TV subscribers are now dissatisfied with their pay TV service, according to research from Parks Associates. The future represents a 100% increase since 2013, according to Parks....

Over Two-Thirds Of U.S. Smartphone Owners Stream Music Daily

A recent Parks Associates report reveals that 68 percent of U.S. smartphone owners listen to streaming music every day, for an average of 45 minutes per day. Amazon Prime Music emerged as the most pop...

Morning Read: Pharma Changes Afoot As Valeant Courts A New CEO And Novartis U.S. Head Exits

Less than half of caregivers with a smartphone use apps aimed at caregivers, according to a report by Parks Associates. — MobiHealthNews From the article "Morning Read: Pharma Changes Afoot As Vale...